Cure Pharmaceutical Holding Corp.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Cure Pharmaceutical Holding Corp. - overview
Established
2011
Location
Oxnard, CA, US
Primary Industry
Pharmaceuticals
About
Cure Pharmaceutical Holding Corp. focuses on developing innovative orodispersible dosage forms, including its flagship product, CUREFilm®, which enhances drug delivery and patient compliance. Founded in 2011 and headquartered in Oxnard, US, Cure Pharmaceutical specializes in advanced drug delivery systems. The firm has not undergone any reported pivots or changes in its business strategy.
The company is co-led by CEOs Nancy Duitch and Rob Davidson. Cure Pharmaceutical specializes in developing orodispersible dosage forms, particularly through its flagship product, CUREFilm®. This delivery system allows for sublingual and buccal administration, which facilitates rapid absorption into the bloodstream, thereby minimizing first-pass metabolism. The CUREFilm® line enhances patient compliance by providing an alternative to traditional oral solids and injections, targeting various applications in pharmaceuticals, vaccines, and nutraceuticals.
The company focuses on addressing healthcare challenges, such as poor bioavailability and medication non-adherence, in underserved markets across North America and aims to expand into Europe and Asia. Cure Pharmaceutical reported revenues of USD 4. 35 mn for the year 2023, with an EBITDA of USD -5. 32 mn.
The revenue model includes direct sales to healthcare providers and pharmacies, as well as licensing agreements for its patented drug delivery technologies. This B2B structure allows pharmacies and healthcare institutions to distribute CUREFilm® products effectively, while collaborations with pharmaceutical companies may enhance existing drug formulations, creating additional revenue streams. Cure Pharmaceutical plans to launch new products, including expanded applications of its CUREFilm® range, aimed at enhancing patient care by 2024. The company is targeting geographic expansion into European and Asian markets, taking advantage of the growing need for innovative drug delivery systems.
Recent funding will support these initiatives, focusing on product development and market entry strategies that align with its growth objectives.
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Specialty Pharmaceuticals
Website
www.curepharmaceutical.com
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
Cure Pharmaceutical Holding Corp. - timeline of key events
Cure Pharmaceutical Holding Corp. - financials
| Fiscal Year Ended | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 84,165 | 180,404 | 583,941 | 623,000 | 2,051,000 | - | - | - |
| % Revenue Growth (YoY) | - | 114.3% | 223.7% | 6.7% | 229.2% | - | - | - |
| EBITDA (USD) | (3,753,636) | (5,689,137) | (5,303,274) | (11,858,000) | (16,519,000) | - | - | - |
| Operating Income (USD) | (3,926,244) | (7,342,107) | (7,557,691) | (13,692,000) | (18,958,000) | - | - | - |
| Operating Margin | (4664.9%) | (4069.8%) | (1294.3%) | (2197.8%) | (924.3%) | - | - | - |
| % EBITDA Margin | (4459.9%) | (3153.6%) | (908.2%) | (1903.4%) | (805.4%) | - | - | - |
| NET Income (USD) | (4,157,480) | (8,163,695) | (10,430,873) | (21,373,000) | (30,621,000) | - | - | - |
| % Net Margin | (4939.7%) | (4525.2%) | (1786.3%) | (3430.7%) | (1493.0%) | - | - | - |
Cure Pharmaceutical Holding Corp. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.